Introduction: Dermatological disorders are emerging as important indicators of systemic health and have drastic implications for cardiovascular disease (CVD). Skin and cardiovascular diseases share common pathophysiological mechanisms, including chronic inflammation, oxidative stress, and endothelial dysfunction. These overlapping pathways contribute to the increased cardiovascular (CV) risk observed in patients with inflammatory and genetic dermatological conditions, such as psoriasis, atopic dermatitis, and systemic lupus erythematosus. Methods: This narrative review was conducted by evaluating current evidence from peer-reviewed literature on the association between dermatological disorders and cardiovascular risk. Particular attention was given to pathophysiological mechanisms and therapeutic implications relevant to both specialties. Results and discussion: Since systemic inflammation is a major risk factor for CVD, treatments that reduce the inflammatory burden represent promising strategies to prevent or mitigate cardiovascular complications in patients with dermatological conditions. Traditional therapies (e.g., methotrexate and statins) remain the gold standard to reduce CV risk. In addition, advances in the field of inflammation-such as inhibitors targeting IL-17 and IL-23 pathways-along with new systemic biomarkers and the development of targeted therapies, are paving the way for improved patient stratification and personalized approaches. Conclusions: This review highlights the importance of interdisciplinary collaboration in optimizing patient outcomes and emphasizes the need for closer integration of dermatological and cardiological expertise. Future research should focus on clarifying molecular mechanisms, identifying therapeutic targets, and refining shared clinical guidelines. By bridging dermatology and cardiology, this review underscores the potential for earlier detection, better risk prediction, and integrated management of coexisting dermatological and cardiovascular conditions.
Bridging dermatology and cardiology. The link between skin lesions and cardiovascular risk / Simeone, B., Dietrich, E., Sarto, G., Greco, M.E., Forte, M., Picchio, V., Rocco, E., Spadafora, L., Bernardi, M., Schirone, L., Schiavon, S., D'Ambrosio, L., Vecchio, D., Valenti, V., Sciarretta, S., Falco, E.D., Peruzzi, M., Greco, E., Frati, G., Proietti, I., et al.. - In: CURRENT CARDIOLOGY REVIEWS. - ISSN 1573-403X. - 22:(2026). [10.2174/011573403x428201260108121737]
Bridging dermatology and cardiology. The link between skin lesions and cardiovascular risk
Simeone, Beatrice
;Dietrich, Elisa
;Sarto, Gianmarco;Greco, Maria Elisabetta;Forte, Maurizio;Picchio, Vittorio;Spadafora, Luigi;Schirone, Leonardo;Schiavon, Sonia;D'Ambrosio, Luca;Vecchio, Daniele;Valenti, Valentina;Sciarretta, Sebastiano;Falco, Elena De;Peruzzi, Mariangela;Greco, Ernesto;Frati, Giacomo;Proietti, Ilaria;Potenza, Concetta
2026
Abstract
Introduction: Dermatological disorders are emerging as important indicators of systemic health and have drastic implications for cardiovascular disease (CVD). Skin and cardiovascular diseases share common pathophysiological mechanisms, including chronic inflammation, oxidative stress, and endothelial dysfunction. These overlapping pathways contribute to the increased cardiovascular (CV) risk observed in patients with inflammatory and genetic dermatological conditions, such as psoriasis, atopic dermatitis, and systemic lupus erythematosus. Methods: This narrative review was conducted by evaluating current evidence from peer-reviewed literature on the association between dermatological disorders and cardiovascular risk. Particular attention was given to pathophysiological mechanisms and therapeutic implications relevant to both specialties. Results and discussion: Since systemic inflammation is a major risk factor for CVD, treatments that reduce the inflammatory burden represent promising strategies to prevent or mitigate cardiovascular complications in patients with dermatological conditions. Traditional therapies (e.g., methotrexate and statins) remain the gold standard to reduce CV risk. In addition, advances in the field of inflammation-such as inhibitors targeting IL-17 and IL-23 pathways-along with new systemic biomarkers and the development of targeted therapies, are paving the way for improved patient stratification and personalized approaches. Conclusions: This review highlights the importance of interdisciplinary collaboration in optimizing patient outcomes and emphasizes the need for closer integration of dermatological and cardiological expertise. Future research should focus on clarifying molecular mechanisms, identifying therapeutic targets, and refining shared clinical guidelines. By bridging dermatology and cardiology, this review underscores the potential for earlier detection, better risk prediction, and integrated management of coexisting dermatological and cardiovascular conditions.| File | Dimensione | Formato | |
|---|---|---|---|
|
Simeone_Bridging_2025.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
3.52 MB
Formato
Adobe PDF
|
3.52 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


